MARKET

APRE

APRE

Aprea Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.450
+0.030
+0.68%
Pre Market: 4.510 +0.06 +1.35% 09:01 04/14 EDT
OPEN
4.390
PREV CLOSE
4.420
HIGH
4.490
LOW
4.310
VOLUME
4.61K
TURNOVER
--
52 WEEK HIGH
41.12
52 WEEK LOW
4.310
MARKET CAP
94.28M
P/E (TTM)
-1.7590
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 1d ago
Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatment of Acute Myeloid Leukemia (AML)
GlobeNewswire · 5d ago
BRIEF-Aprea Therapeutics Receives FDA Orphan Drug Designation For Eprenetapopt For The Treatment Of Acute Myeloid Leukemia
reuters.com · 5d ago
DJ Aprea Gets FDA Orphan Designation for Eprenetapopt in Acute Myeloid Leukemia >APRE
Dow Jones · 5d ago
Aprea Therapeutics shares rise after leukemia treatment gets FDA orphan drug status
Aprea Therapeutics shares jump ([[APRE]] +15.3%) announces that the U.S. FDA has granted Orphan Drug designation to eprenetapopt for treatment of acute myeloid leukemia ((AML)).Orphan Drug status is granted by the
Seekingalpha · 5d ago
Aprea Therapeutics on Wednesday Received FDA Orphan Drug Designation for eprenetapopt for Treatment of Acute Myeloid Leukemia
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=797420
Benzinga · 6d ago
The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 30)
Benzinga · 03/31 11:41
DJ Aprea Therapeutics Is Maintained at Sector Perform by RBC Capital
Dow Jones · 03/17 11:59
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APRE. Analyze the recent business situations of Aprea Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APRE stock price target is 7.50 with a high estimate of 10.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 80
Institutional Holdings: 10.30M
% Owned: 48.63%
Shares Outstanding: 21.19M
TypeInstitutionsShares
Increased
25
1.49M
New
15
648.18K
Decreased
16
5.30M
Sold Out
13
3.36M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.86%
Pharmaceuticals & Medical Research
+0.68%
Key Executives
Chairman/President/Chief Executive Officer/Director
Christian Schade
Chief Financial Officer/Senior Vice President/Secretary
Scott Coiante
Senior Vice President/Chief Scientific Officer
Lars Abrahmsen
Senior Vice President
Eyal Attar
Vice President - Business Development
Gregory Korbel
Other
Gregory Wessels
Lead Director/Independent Director
John Henneman
Director
Michael Kelly
Director
Fouad Namouni
Director
Richard Peters
Independent Director
Johan Christenson
Independent Director
Guido Magni
Independent Director
Bernd Seizinger
No Data
About APRE
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.

Webull offers kinds of Aprea Therapeutics Inc stock information, including NASDAQ:APRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APRE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APRE stock methods without spending real money on the virtual paper trading platform.